Holen Sie sich die Stockscreener-App
54.31
0.15%
0.08
Schlusskurs vom Vortag:
$54.23
Offen:
$54.28
24-Stunden-Volumen:
1.12M
Relative Volume:
0.53
Marktkapitalisierung:
$4.47B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-14.48
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+0.11%
1M Leistung:
+0.95%
6M Leistung:
+12.33%
1J Leistung:
+74.07%
1-Tages-Spanne:
$54.26
$54.35
1-Wochen-Bereich:
$54.22
$54.41
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.31 | 4.46B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Intech Investment Management LLC Sells 16,635 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. (0K4) stock outperform value peersPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
What dividend safety rating applies to Akero Therapeutics Inc. (0K4) stockWeekly Investment Report & Free Reliable Trade Execution Plans - newser.com
Is Akero Therapeutics Inc. stock a smart buy before Fed meetingIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is Akero Therapeutics Inc. (0K4) stock a top pick for value investorsPrice Action & Reliable Price Breakout Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonTreasury Yields & Daily Profit Focused Screening - newser.com
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsMarket Growth Report & Real-Time Volume Analysis - newser.com
Is Akero Therapeutics Inc. (0K4) stock prepared for digital transitionJuly 2025 Setups & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Akero Therapeutics Inc. stock a buy before product launches2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Why Akero Therapeutics Inc. (0K4) stock attracts HNW investorsJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Is Akero Therapeutics Inc. stock attractive for growth ETFsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Is Akero Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Is Akero Therapeutics Inc. stock attractive for income investorsProduct Launch & Advanced Technical Signal Analysis - newser.com
Bank of New York Mellon Corp Increases Stake in Akero Therapeutics, Inc. $AKRO - MarketBeat
Heatmap analysis for Akero Therapeutics Inc. and competitors - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunityPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com
Will Akero Therapeutics Inc. stock keep outperforming rivals2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
What drives Akero Therapeutics Inc stock priceCurrency Fluctuation Impact & Start Building Capital with Zero Risk - earlytimes.in
Akero Therapeutics shares breakthrough MASH treatment data - Traders Union
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes $2.21 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
How rising interest rates impact Akero Therapeutics Inc. stock2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economyTrade Analysis Report & Daily Oversold Bounce Ideas - newser.com
Using RSI to spot recovery in Akero Therapeutics Inc.July 2025 Decliners & Smart Investment Allocation Insights - newser.com
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):